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Disruption of ER−mitochondria signalling
in fronto-temporal dementia and related
amyotrophic lateral sclerosis
Dawn H. W. Lau 1, Naomi Hartopp1, Natalie J. Welsh1, Sarah Mueller1, Elizabeth B. Glennon1, Gábor M. Mórotz1,
Ambra Annibali1, Patricia Gomez-Suaga1, Radu Stoica1, Sebastien Paillusson1 and Christopher C. J. Miller1
Abstract
Fronto-temporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two related and incurable
neurodegenerative diseases. Features of these diseases include pathological protein inclusions in affected neurons with
TAR DNA-binding protein 43 (TDP-43), dipeptide repeat proteins derived from the C9ORF72 gene, and fused in sarcoma
(FUS) representing major constituent proteins in these inclusions. Mutations in C9ORF72 and the genes encoding TDP-
43 and FUS cause familial forms of FTD/ALS which provides evidence to link the pathology and genetics of these
diseases. A large number of seemingly disparate physiological functions are damaged in FTD/ALS. However, many of
these damaged functions are regulated by signalling between the endoplasmic reticulum and mitochondria, and this
has stimulated investigations into the role of endoplasmic reticulum-mitochondria signalling in FTD/ALS disease
processes. Here, we review progress on this topic.
Facts
● ER−mitochondria signalling is disrupted by a
number of FTD/ALS-linked insults. These include
TDP-43, FUS, mutant SOD1, and loss of the Sigma-1
receptor.
● For TDP-43 and FUS this disruption involves
breaking of the VAPB−PTPIP51 ER−mitochondria
tethering proteins via activation of GSK3β.
Open questions
● How do TDP-43 and FUS activate GSK3β?
● How does GSK3β regulate the VAPB−PTPIP51
interaction; is it via direct phosphorylation of one or
both of these tethering proteins?
● Do other FTD/ALS insults also perturb ER
−mitochondria contacts and signalling via disruption
of the VAPB−PTPIP51 tethers? In particular, do
pathogenic dipeptide repeat proteins derived from
mutant C9ORF72 damage the VAPB−PTPIP51
tethers and if so, does this involve GSK3β?
● Are ER−mitochondria contacts and the VAPB
−PTPIP51 tethers damaged in human disease tissues?
● Is damage to ER−mitochondria signalling and the
VAPB−PTPIP51 tethers an early pathogenic feature?
● Can ER−mitochondria signalling and the VAPB
−PTPIP51 tethers be targeted pharmacologically?
Fronto-temporal dementia and amyotrophic
lateral sclerosis are related diseases
Fronto-temporal dementia (FTD), also known as
fronto-temporal lobar degeneration, is characterised by
neurodegeneration and neuronal loss in frontal and
anterior temporal brain lobes. This leads to language
impairment as well as behavioural and personality chan-
ges1. FTD is the second most common cause of presenile
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dementia after Alzheimer’s disease2. Amyotrophic lateral
sclerosis (ALS) is the most common form of motor neu-
ron disease. It involves degeneration of lower motor
neurons in the brainstem and spinal cord, and of upper
motor neurons in the motor cortex which together leads
to progressive paralysis and muscle wasting. Survival time
from symptom onset is only about 3 years3. There is no
cure nor even effective disease-modifying treatments for
either FTD or ALS.
Although originally classiﬁed as different diseases, FTD
and ALS are now known to be clinically, genetically and
pathologically linked. Approximately 15% of FTD patients
display clinical ALS features and up to 15% of ALS
patients develop symptoms consistent with a clinical
deﬁnition of FTD4,5. Moreover, recent genetic and
pathological studies have conﬁrmed these links2.
Both FTD and ALS have strong genetic components,
and mutations in a large number of genes are now known
to be causative for inherited familial forms of these dis-
eases. Indeed, there are now over 80 genes that have been
linked to genetic forms of FTD/ALS and related motor
neuron disorders6 (and see http://alsod.iop.kcl.ac.uk).
Some of these mutant genes are more closely linked to
either FTD or ALS. For example, mutations in MAPT,
which encodes the microtubule-associated protein Tau,
and PGRN, which encodes Progranulin, are linked almost
exclusively to FTD. Likewise, mutations in SOD1 that
encodes the anti-oxidant enzyme Cu/Zn Superoxide
dismutase-1 (SOD1) primarily causes ALS. However,
mutations in a number of other genes cause dominantly
inherited forms of both FTD and ALS. These include
TARDP and FUS/TLS that encode the nucleic acid bind-
ing proteins TDP-43 and FUS, and C9ORF72 whose
encoded protein has been linked to autophagy2.
Interestingly, a number of these encoded proteins linked
to familial FTD, ALS, and FTD/ALS also form pathologies
of these diseases. Thus, Tau and SOD1 inclusions are seen
in FTD and ALS respectively while TDP-43 and FUS
inclusions form major pathologies in FTD/ALS2,7. Muta-
tions in C9ORF72 are causative for large numbers of
familial FTD/ALS cases (up to about 30% FTD, 50% ALS
and 80% FTD/ALS cases)8–14. The C9ORF72 mutations
involve expansion of an intronic hexanucleotide
GGGGCC repeat and this repeat has been shown to be
translated to generate dipeptide repeat proteins (DPRs) by
a process termed repeat-associated non-ATG transla-
tion15–17. These DPRs are either poly- Gly-Pro, Pro-Ala,
Gly-Ala, Pro-Arg or Gly-Arg and are deposited in FTD/
ALS cases15–17. Some of these DPRs have been shown to
be neurotoxic18. Interestingly, genetic forms of FTD/ALS
caused by the C9ORF72 mutations also often present with
TDP-43 pathology and transgenic c9orf72 mice or mice
expressing DPRs can develop TDP-43 pathology7,19–23.
Together, these data suggest a link between DPRs and
TDP-43. However, while DPR toxicity is the favoured
disease mechanism for mutant C9ORF72, alternative
hypotheses have been proposed. These involve hap-
loinsufﬁciency and loss of c9orf72 function, and also the
formation of RNA foci involving the GGGGCC repeat.
These foci may sequester mRNA binding and/or other
proteins to disrupt proper expression of heterologous
genes2. Nevertheless, together these data show that there
is some convergence of genetic and pathological pheno-
types in FTD/ALS.
FTD/ALS is characterised by damage to a variety
of cellular functions and many of these are
regulated by signalling between the ER and
mitochondria
A number of physiological functions are perturbed in
FTD/ALS2,3,24,25. These include damage to organelles and
in particular mitochondria and the ER. Indeed, altered
bioenergetics and activation of the unfolded protein
response (UPR) are major features of FTD/ALS26–28.
Disruption to Ca2+ homeostasis and changes to lipid
metabolism are also seen in both diseases29,30. Axonal
transport is a process by which proteins and organelles are
transported to and from synapses and neurons are heavily
dependent on this process. This is because most proteins
are synthesised in cell bodies which then need to be
transported to their ﬁnal destinations including synapses;
this transport can involve relatively long distances.
Damage to axonal transport is a common feature of FTD/
ALS31,32. Defective autophagy is also strongly implicated
in FTD/ALS and some mutant genes linked to autophagy
such as those encoding optineurin, ubiquilin-2, and
SQSTM1/p62 are causative for familial forms of FTD/
ALS33,34. Damage to autophagy may contribute to the
failure of affected neurons to clear pathological protein
aggregates in disease27,35. Mitophagy is specialised form of
autophagy that involves the clearance of damaged mito-
chondria36. As stated above, damage to mitochondria
contributes to FTD/ALS and so perturbations to mito-
phagy can lead to a failure to eliminate such damaged
organelles. Finally, inﬂammatory responses are seen in
FTD/ALS where reactive morphologies to astrocytes and
microglia are prominent features along with the presence
of inﬂammatory mediators and cytokines. It is generally
believed that such inﬂammatory responses contribute to
the disease process37,38. Indeed, anti-inﬂammatory agents
can be protective in transgenic models of ALS39.
The biological conundrum is how so many apparently
disparate physiological processes are damaged collec-
tively. The therapeutic challenge is selecting which of
these different processes to prioritise for drug discovery.
A number of recent studies have investigated signalling
between ER and mitochondria in FTD/ALS. ER−mito-
chondria communication involves close physical contacts
Lau et al. Cell Death and Disease  (2018) 9:327 Page 2 of 8
Ofﬁcial journal of the Cell Death Differentiation Association
(10–30 nm distance) between the two organelles such that
up to approximately 20% of the mitochondrial surface is
tightly apposed to ER-membranes40 (Fig. 1a). These
regions of ER are termed mitochondria-associated ER
membranes (MAMs)24,41–45.
The reason for investigating ER−mitochondria signal-
ling is that many of the damaged cell functions described
above that characterise FTD/ALS are regulated by this
signalling. Indeed, ER−mitochondria cross-talk is known
to impact upon the following.
1. ER−mitochondria contacts facilitate phospholipid
exchange between the two organelles. This is
important as the enzymes that synthesise certain
lipids are present in either organelle and so
precursor exchange is required for the production of
these lipids24,41–45. Indeed, MAMs have been shown
to be a specialised type of lipid raft (also known as
detergent-resistant membranes)46.
2. ER−mitochondria contacts facilitate Ca2+ exchange
between the two organelles and in particular uptake
of Ca2+ by mitochondria following its release from
ER stores via inositol 1,4,5-trisphosphate (IP3)
receptors. Such Ca2+ uptake is required by
mitochondria for generating ATP via the
tricarboxylic acid cycle since several mitochondrial
dehydrogenases are Ca2+ regulated47. However,
excessive uptake of Ca2+ by mitochondria can lead
to opening of the mitochondrial permeability
transition pore and signalling for apoptosis24,41–45.
3. ER−mitochondria contacts are required for
mitochondrial biogenesis since mitochondrial ﬁssion
occurs at contact sites and mitochondrial DNA
synthesis is regulated by these contacts48–50.
4. ER−mitochondria contacts regulate intracellular
trafﬁcking of both mitochondria and ER since a
proportion of ER is co-transported with
mitochondria through cells51. Moreover, the Ca2+
sensor mitochondrial Rho GTPase (Miro), which
mediates attachment of mitochondria to kinesin-1
motors for transport, localises to ER−mitochondria
contact sites52–55. In neurons, this trafﬁcking
includes axonal transport.
5. ER−mitochondria contacts are linked to
autophagy56–61. Notably, several groups have shown
that delivery of Ca2+ from ER stores to
mitochondria at MAM regulates autophagosome
formation61–69.
6. ER−mitochondria contacts are linked to ER
stress and the UPR. Several ER protein folding
chaperones are present in MAM, disrupting ER-
mitochondria contacts induces the UPR, and
chemical induction of the UPR increases ER-
mitochondria associations70–72. Moreover,
vesicle-associated membrane protein associated-
protein B (VAPB), which functions as an ER
−mitochondria tethering protein (see below), is
strongly linked to ER stress responses73,74.
7. ER−mitochondria signalling is linked to
formation of the inﬂammasome, a multiprotein
complex involved in the initiation of
inﬂammatory processes and in particular,
proteolytic maturation of the pro-inﬂammatory
cytokine interleukin-1β. Notably, mitochondria-
derived reactive oxygen species induce
recruitment of the NOD-like receptor NLRP3, a
key component of the inﬂammasome to MAM75.
a  CTRL b  VAPB+PTPIP51
Fig. 1 ER−mitochondria contacts in NSC-34 motor neuron cells. Contacts are indicated with red arrows in control cells a and in cells transfected
with the ER−mitochondria tethering proteins VAPB and PTPIP51 b Transfection of VAPB and PTPIP51 dramatically increases ER−mitochondria
contacts. Scale bar = 500 nm
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Thus, damage to ER−mitochondria signalling repre-
sents a plausible route for explaining many pathological
features of FTD/ALS.
ER−mitochondria tethering proteins
Crucial to understanding both the normal roles of ER
−mitochondria signalling and any abnormal role in dis-
ease is knowledge of the mechanisms by which regions of
ER are recruited to mitochondria. It is now generally
accepted that this recruitment involves scaffolding pro-
teins that function to tether the two organelles. A number
of tethering proteins have now been identiﬁed (Fig. 2). In
yeast, proteins of the ER−mitochondria encounter
structure (ERMES) function to connect the two organelles
but ERMES proteins are yeast speciﬁc and no homologues
have been found in mammals76. In mammals, the inter-
action between ER-located IP3 receptors and the mito-
chondrial voltage-dependent anion channel (VDAC) via
Grp75 was originally proposed as a functional tether but
loss of IP3 receptors does not affect ER−mitochondria
contacts, which argues against a direct tethering role40.
Homo- and heterotypic interactions between ER-located
mitofusin-2 and mitochondrial mitofusin-1/2 have also
been proposed as tethers77,78 but other groups have dis-
puted these ﬁndings (see Filadi et al.41 for further dis-
cussion on this topic).
More recently, binding of the integral ER protein VAPB
and the outer mitochondrial membrane protein, protein
tyrosine phosphatase interacting protein 51 (PTPIP51) has
been shown to tether ER with mitochondria79,80 (see Fig. 3
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for VAPB and PTPIP51 domain structures). VAPB binds to
PTPIP51 in many different biochemical assays and mod-
ulating VAPB and PTPIP51 expression induces appropriate
changes in ER−mitochondria contacts (Fig. 1b). Moreover,
manipulating VAPB or PTPIP51 expression alters Ca2+
exchange between the two organelles which is a physiolo-
gical readout of ER−mitochondria contacts79–81. Others
have now replicated and extended these ﬁndings82–86.
Thus, PTPIP51 may also interact with the oxysterol-
binding protein-related proteins ORP5 and ORP8 to reg-
ulate ER−mitochondria contacts83.
Finally, the tail-anchored, PDZ-domain-containing outer
mitochondrial membrane protein SYNJ2BP was shown to
bind to the ribosome-binding protein 1 and this interaction
may act to selectively mediate signalling between mito-
chondria and rough ER87. A number of other proteins have
also been linked to ER−mitochondria signalling, including
B-cell receptor-associated protein 31 (Bap31) and ﬁssion
protein 1 (Fis1), FUN14 domain-containing protein 1
(FUNDC1) and calnexin, and phosphofurin acid cluster
sorting protein 2 (PACS2), but whether these are bonaﬁde
tethering proteins or regulators of ER−mitochondria sig-
nalling is unclear24,41,59,70,88.
ER−mitochondria signalling and the VAPB-
PTPIP51 tethers are disrupted in FTD/ALS
A number of studies have now investigated how FTD/
ALS insults affect ER−mitochondria signalling. Both
TDP-43 and FUS have been shown to disrupt ER−mito-
chondria interactions and this is associated with
decreased binding of VAPB to PTPIP5180,89. TDP-43 and
FUS also perturb Ca2+ exchange between ER and mito-
chondria (which is consistent with a loosening of ER
−mitochondria associations) and mitochondrial ATP
production which is dependent upon this Ca2+
exchange80,89. Moreover, the effects of TDP-43 and FUS
on ER−mitochondria contacts and the VAPB−PTPIP51
tethers are linked to activation of glycogen synthase
kinase-3β (GSK3β) (Fig. 4)80,89. GSK3β activation disrupts
binding of VAPB to PTPIP51 and GSK3β inhibitors cor-
rect FUS induced damage to ER−mitochondria signal-
ling80,89. GSK3β is strongly associated with
neurodegenerative disease. For example, GSK3β is acti-
vated in induced pluripotent stem cell neurons derived
from Alzheimer’s disease patients and regulates Aβ pro-
duction, and phosphorylates Tau so that it resembles that
seen in dementia90–92.
Other studies have linked loss-of-function mutations in
the Sigma-1 receptor to familial FTD, ALS and other
forms of motor neuron disease93–99. The Sigma-1 receptor
is an ER protein enriched in MAM that facilitates IP3
receptor-mediated delivery of Ca2+ from ER stores to
mitochondria; as such the Sigma-1 receptor enhances
mitochondrial ATP production100–102. The Sigma-1
receptor gene resides on chromosome 9 and it has been
suggested that the disease-causing mutations in some of
these families may involve C9ORF72 (which also resides
on chromosome 9) and not the mutant Sigma-1 recep-
tor103. However, further mutations in the Sigma-1
receptor have been linked to FTD and motor neuron
disease and some of these have formally excluded the
involvement of mutant C9ORF7293,94,97,98. Moreover, a
variety of experimental studies have provided mechanistic
data to link loss of the Sigma-1 receptor to FTD/ALS.
Firstly, Sigma-1 receptor knockout mice display features
of ALS. Secondly, loss of Sigma-1 receptor exacerbates
disease in other transgenic mouse models of ALS and can
induce features of FTD/ALS in cellular models. Finally,
Sigma-1 receptor agonists have proved beneﬁcial in some
models of FTD/ALS93,94,104–109. Notably, disease mutant
Sigma-1 receptor variants and loss of the Sigma-1
receptor have all been shown to reduce ER−mitochon-
dria contacts and signalling although the mechanisms
underlying these effects are not known (Fig. 4)93,94,98.
Finally, ALS mutant SOD1 has also been shown to reduce
ER−mitochondria contacts and signalling, and this is
linked to a selective loss of the Sigma-1 receptor from
MAM94. Thus, four different FTD/ALS-linked genetic
insults, TDP-43, FUS, the Sigma-1 receptor and mutant
SOD1, have all been shown to disrupt ER−mitochondria
contacts and signalling and where investigated (TDP-43
GSK3β
FUS/TDP-43
VAPB PTPIP51
Disrupted ER-mitochondria 
signaling
Sigma-1R/mSOD1
Fig. 4 Model showing how different FTD/ALS insults disrupt ER
−mitochondria signalling. TDP-43 and FUS activate GSK3β which
then leads to breaking of the VAPB−PTPIP51 tethering proteins,
loosening of ER−mitochondria contacts and disruption to signalling.
The mechanisms by which TDP-43 and FUS activate GSK3β and how
GSK3β inﬂuences the VAPB−PTPIP51 interaction are not known.
GSK3β may phosphorylate VAPB and/or PTPIP51 to regulate directly
their binding or alter binding indirectly via other molecules. The
molecular mechanisms linking the Sigma-1 receptor and mutant
SOD1 to ER-mitochondria communication are less well characterised.
They may alter ER-mitochondria signalling via GSK3β and the VAPB
−PTPIP51 tethers or via other routes, including direct effects on the
tethers
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and FUS) this involves breaking of the VAPB−PTPIP51
tethers80,89,93,94,98.
Interestingly, mutations in VAPB also cause some forms
of ALS and related motor neuron diseases2,3. The best
characterised mutant involves a proline to serine sub-
stitution at amino acid 56 VAPB-P56S110. Compared to
wild-type, VAPB-P56S displays increased binding to
PTPIP5179. This is in apparent contrast to other FTD/
ALS mutant proteins which reduce ER−mitochondria
contacts and the VAPB−PTPIP51 interaction80,89,93,94,98.
However, VAPB-P56S expression is markedly lower than
wild-type and also reduces total VAPB levels73,111. Thus,
despite its increased binding to PTPIP51, the overall effect
of VAPB-P56S may be to reduce ER−mitochondria con-
tacts. Interestingly, reduced levels of VAPB are seen in
sporadic ALS patients112.
Is damage to ER−mitochondria signalling and
MAM a 'driver' of disease, or a response to
damage of other physiological processes?
The above studies that demonstrate damage to ER
−mitochondria signalling in FTD/ALS provide a plausible
mechanism for explaining many disease features. Thus,
primary insults such as TDP-43, FUS, loss of the Sigma-1
receptor and mutant SOD1 may damage ER−mitochon-
dria signalling which in turn perturbs other downstream
cellular functions such as Ca2+ homeostasis, lipid meta-
bolism, axonal transport, mitochondrial function and ER
stress. In this scenario, damage to ER−mitochondria
signalling represents a driver of the disease process and
therapeutic correction of this damage may correct many
disease features (Fig. 4). However, an alternative possibi-
lity is that alterations to ER−mitochondria signalling in
disease represent a physiological response to other
damaged features. Clearly, if targeting ER−mitochondria
signalling is to be a valid drug target for FTD/ALS, then it
is important to properly discriminate between these
possibilities.
A number of lines of evidence suggest that disruption to
ER−mitochondria signalling is a driver of disease. Firstly,
mutations in VAPB cause some familial forms of ALS and
these mutants reduce VAPB levels; selective reduction of
VAPB is also seen in spinal cords of sporadic ALS
patients110–112. Such loss of VAPB impairs ER−mitochon-
dria communication79,80. Secondly, mutant loss of the
Sigma-1 receptor, a key MAM protein also causes familial
FTD/ALS and enhancing Sigma-1 receptor function is
protective in FTD/ALS models93,94,98. Thirdly, over-
expression of VAPB to restore ER−mitochondria tethering
and signalling61,80 is protective in mutant SOD1 transgenic
mice113. Finally, Parkinson’s disease-related α-synuclein
disrupts the VAPB−PTPIP51 tethers and overexpression of
VAPB to correct this disruption also corrects α-synuclein-
linked damage to Ca2+ homeostasis114.
Future studies to address these issues further will
involve determining whether ER−mitochondria contacts
are perturbed in human FTD/ALS tissues and whether
any damage is an early disease feature; early pathogenic
changes are believed to be the most important. However,
such studies are likely to be compromised by the quality
of preservation in most post-mortem tissue. Utilising
neurons derived from induced pluripotent stem cells
carrying FTD/ALS associated mutations provides an
alternative route. In a complementary fashion, determin-
ing whether damaged ER-mitochondria contacts and
signalling are early pathogenic events in transgenic mouse
models of FTD/ALS will be of major value. Finally,
investigating whether experimental correction of
damaged ER-mitochondria contacts corrects other disease
features will provide evidence as to whether targeting the
ER-mitochondria axis is a valid drug target for FTD/ALS.
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